European Urology
Publisher: Elsevier · ISSN 0302-2838 · 79 articles
- Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18
- Re: PSMA PET for Lymph Nodes in Intermediate-risk PC
- Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol 2026;89:550–551
- Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol 2026;90:176
- Re: Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial
- Re: Impact of Circulating Tumor DNA and Copy-number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated with Salvage High-dose Chemotherapy: BLOG TITLE: Value of ctDNA in Advanced Germ Cell Tumors
- Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer
- Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non–muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely
- Re: Prophylactic Ureteral Stenting in Kidney Transplantation: A Multivariable and Propensity Score-matched Analysis of 3407 Recipients from NSQIP Transplant
- Re: Microultrasonography-guided Versus MRI-guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
- Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU–EANM–ESTRO–ESUR–ISUP–SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.013
- Re: A Randomized Controlled Trial Comparing En-bloc Versus Lobe-by-lobe HoLEP: Surgical Efficiency and Early Continence Outcomes
- Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial
- Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study
- Re: Perioperative Apalutamide In High-risk Localized Prostate Cancer
- Re: Aldo Brassetti, Gabriele Tuderti, Umberto Anceschi, et al. Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.019
- Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer
- Reply to Dachun Jin, Chi-Fai Ng, and Peter Ka-Fung Chiu’s Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.020
- Reply to Sho Todo, Keiichiro Kitahama, and Kentaro Inamura's Letter to the Editor re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. 2026 Apr 25:S0302-2838(26)02060-9
- 177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial
- Re: Arie Parnham, Maarten Albersen, Benjamin Ayres, et al. European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update. Eur Urol 2026;90:60–71
- Re: Kari A. O. Tikkinen, Maura Marcucci, Alex L. E. Halme, et al. Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-controlled POISE-3 Trial. Eur Urol 2026;90:140–9
- Reply to Roberto Mario Scarpa’s Letter to the Editor: Sham or Active Control in MIST Trials? A False Methodological Dichotomy. re: Baboudjian M, Nunzio C, Elterman D, et al. What is the Standard Comparator of Minimally Invasive Surgical Therapies (MIST) for Benign Prostatic Obstruction? Medical Versus Surgical Treatment. Eur Urol. 2026 Aug;90(2):95-97.
- In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023
- Epidemiology and Modifiable Risk Factors for Benign Prostatic Enlargement and Related Lower Urinary Tract Symptoms: A Systematic Review with Meta-analysis
- Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr
- Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial
- Prostate Cancer Proteomics: Towards Refined Risk Prediction
- Epidemiology, Risk Factors, and Prevention of Prostate Cancer
- Surgery in Motion: Different Surgical Techniques for Inguinal Lymph Node Dissection in Penile Cancer